Mary E. Russell
Presidente presso Ascent Translational Sciences, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Vance Brown | M | 54 | 23 anni | |
John Sorenson | M | 56 | 22 anni | |
Wendy Carruthers | F | 55 | 20 anni | |
Milad Girgis | M | - | 20 anni | |
Colin Morrison | M | - | 22 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
John Onuscheck | M | 57 | - | |
Nancy E. Isaac | F | 62 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 8 anni |
Scott William Kraus | M | 54 | - | |
Arthur Rosenthal | M | 77 | 11 anni | |
Richard Batt | M | 55 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 anni |
Ernest Mario | M | 85 | 15 anni | |
David Milne | M | 61 | 6 anni | |
Uwe E. Reinhardt | M | 87 | 13 anni | |
Maulik Nanavaty | M | 62 | - | |
Kristen Ambrose | F | 47 | 18 anni | |
Michael D. Laufer | M | 65 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 16 anni |
Renard Charity | M | - | 5 anni | |
René Spaargaren | M | - | 7 anni | |
James W. Fitzsimmons | M | - |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 14 anni |
Fernando di Caprio | M | - | 7 anni | |
Gregg Costantino | M | - | 4 anni | |
Terese Bogucki | F | - |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | - |
Doug Alleavitch | M | 63 | 5 anni | |
Kristina Johnson | M | 67 | 3 anni | |
Bill Densel | M | 56 | 2 anni | |
Larry F. Doll | M | - | 2 anni | |
Griffeth Tully | M | - | 8 anni | |
Greg Welsh | M | 61 | 10 anni | |
David Ben-Ami | M | 63 | 2 anni | |
Kevin J. Sierks | M | 51 | 2 anni | |
Kenneth H. Haas | M | 73 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 anni |
Bonnie J. Stearns | F | 77 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 11 anni |
Samuel L. Omaleki | M | 63 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 7 anni |
Randall Ban | M | 59 | 2 anni | |
Lorenzo Chiozzia | M | - | - | |
Robert DeBenedetto | M | - | 8 anni | |
Edward Randolph | M | 66 | 4 anni | |
Steve C. de Baca | M | 56 | 8 anni | |
Marna Bronfen-Moore | F | 57 | 8 anni | |
Bryan McDonough | M | - | 14 anni | |
Kevin C. Smith | M | 63 | 11 anni | |
Peter Sommerness | M | - | 13 anni | |
Kerry Bennett | M | - | 4 anni | |
Kenneth Daignault | M | - | 14 anni | |
E. Lynne Kelley | M | 61 | 2 anni | |
Stephanie Webber | F | - | 8 anni | |
Carl H. Jacobs | M | - | 5 anni | |
Stephen Keaney | M | 61 | 4 anni | |
Randy Nuernberg | M | - | 9 anni | |
John Groetelaars | M | 58 | 7 anni | |
Kamal Ramzipoor | M | - | 6 anni | |
Nancy Lelicoff | F | - | 4 anni | |
Randel Richner | F | 68 | 9 anni | |
Dean MacIntosh | F | 64 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 anni |
Kathy Horton | F | - | 7 anni | |
Edmund J. Roschak | M | 57 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 13 anni |
Guy Neev | M | 57 | 1 anni | |
Cary B. Cole | M | 57 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 12 anni |
Jennifer Foley | F | - | 4 anni | |
Richard J. Linder | M | 54 | - | |
John E. Pepper | M | 85 | 7 anni | |
Nancy-Ann DeParle | F | 67 | 3 anni | |
Russell W. Felkey | M | 73 | 2 anni | |
Stephen Okland | M | 60 | 3 anni | |
Michael Everett | M | 74 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 3 anni |
Ursula Burns | F | 65 | 7 anni | |
Christine R. Kowalski | F | 67 | 4 anni | |
Robert Bernard Hargadon | M | 67 | 8 anni | |
Marye Anne Fox | M | 76 | 9 anni | |
Matthew Jenusaitis | M | 63 | 2 anni | |
Michel Darnaud | M | 74 | 7 anni | |
Henry C. Tung | M | 65 | 5 anni | |
Morten C. Nielsen | M | 68 | 5 anni | |
Francis P. Grillo | M | 61 | 10 anni | |
Maria Degois Sainz | F | 58 | 2 anni | |
William F. McConnell | M | 74 | 3 anni | |
Mark Bartell | M | 63 | - | |
Michael J. Ryan | M | 45 | - | |
Buzz Benson | M | 69 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 8 anni |
Lukas Roush | M | 46 | 3 anni | |
Amr Salahieh | M | - | 4 anni | |
V. Kadhiresan | M | - | 1 anni | |
Samuel F. Straface | M | - | 4 anni | |
James Robert Pray | M | - | 5 anni | |
Fredericus Colen | M | 71 | 9 anni | |
Howard V. Kelly | M | 66 | 1 anni | |
Jacques Gutedel | M | - | - | |
Isabella R. Abati | F | 64 | 4 anni | |
Henry Kay | M | 79 | 10 anni | |
Winifred Swan | F | 59 | 5 anni | |
Charles Carignan | M | - | 3 anni | |
David R. Kressler | M | - | 14 anni | |
Thomas V. Ressemann | M | - | 2 anni | |
George Harter | M | 67 | 5 anni | |
Yu Te Chang | M | - | - | |
Silvano Cominelli | M | 57 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 anni |
Dennis A. Ocwieja | M | 78 | 5 anni | |
David Toohey | M | 67 | 6 anni | |
Thomas Prescott | M | 68 | 1 anni | |
Jeannette Bankes | F | 53 | 15 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mary E. Russell
- Contatti personali